The development of 3-D transesophageal echo (TEE) just a few years ago has enabled a new generation of interventional procedures to be performed, which otherwise...
The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents...
Methodist DeBakey Heart and Vascular Center in Houston, Tex., has leveraged new imaging and interventional technologies to help contain and reduce costs, increase patient volume and revenues and...
August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to...
St. Jude Medical Inc. said it plans to acquire AGA Medical Holdings Inc. for about $1.3 billion. The purchase will expand St. Jude’s cardiac device offerings with a portfolio of transcatheter...
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is a major risk factor for developing emboli leading to stroke. A new approach to preventing embolisms and stroke is...
In addition to the FDA-cleared Gore Helex and the AGA Amplatzer transcatheter devices for atrial septal defects (ASDs), there are several others in development or already cleared for use outside...
Transcatheter structural heart repair devices deployed in the cath lab have largely replaced open-heart surgery as the therapy of choice. Percutaneously deployed septal occluders make it possible...
